Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1052583 | 0.81 | KAT2B (0.42) | KDM4EHSD17B10HRH3KMT2ACA12 | |
| SCHEMBL3738350 | 0.80 | KAT2B (0.41) | KDM4EHSD17B10HRH3KMT2ACA12 | |
| SCHEMBL3733975 | 0.76 | CA12 (0.49) | KMT2ACA12BRD4BRPF1CA9 | |
| SCHEMBL6436320 | 0.76 | CA12 (0.49) | KDM4EKMT2ACA12BRD4BRPF1 | |
| SCHEMBL3737684 | 0.74 | CA12 (0.53) | KDM4EHSD17B10KMT2ACA12BRD4 | |
| SCHEMBL3728433 | 0.72 | KAT2B (0.45) | KDM4EHSD17B10CA12BRD4BRPF1 | |
| SCHEMBL3732232 | 0.69 | APP (0.43) | HSD17B10HRH3KMT2AALDH1A1 | |
| SCHEMBL3733019 | 0.69 | CYP1A2 (0.44) | KMT2A | |
| SCHEMBL1052536 | 0.69 | KAT2B (0.47) | KDM4EKMT2ACA12BRD4BRPF1 | |
| SCHEMBL1052534 | 0.69 | CA12 (0.47) | KDM4EHSD17B10DRD3KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875624-B2 | administering a cancer patient 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one in the treatment of disorders relating to cell adhesion and metastatic processes; for monitoring the effects of drug by measuring the levels of ICAM, VCAM, or E-selectin in the patient | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | CHIRON CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239825-A1 | Modulation of inflammatory and metastatic processes | VCAM1, EPCAM, ICAM1 | KDM4E 4739/4885HSD17B10 3905/4885DRD3 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.